Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1”

380 trials

Showing 20 of 380 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Testing effectiveness (Phase 2)Study completedNCT02031458
What this trial is testing

Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 667
Post-approval studies (Phase 4)UnknownNCT03313544
What this trial is testing

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Who this might be right for
MelanomaNon-small CellLung Cancer
Assistance Publique Hopitaux De Marseille 50
Testing effectiveness (Phase 2)Looking for participantsNCT06892548
What this trial is testing

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Who this might be right for
Advanced Lung Cancer
BioNTech SE 594
Testing effectiveness (Phase 2)UnknownNCT03753243
What this trial is testing

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Who this might be right for
Prostate Cancer
Mark Garzotto, MD 32
Large-scale testing (Phase 3)Looking for participantsNCT06712355
What this trial is testing

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Who this might be right for
Extensive-stage Small-cell Lung Cancer
BioNTech SE 621
Testing effectiveness (Phase 2)Study completedNCT05535569
What this trial is testing

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Who this might be right for
Recurrent/Metastatic Gastric Cancer
Yonsei University 50
Large-scale testing (Phase 3)WithdrawnNCT03881111
What this trial is testing

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Who this might be right for
Esophageal Neoplasms
Merck Sharp & Dohme LLC
Early research (Phase 1)Looking for participantsNCT07161414
What this trial is testing

Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Who this might be right for
Advanced Solid Tumors
AstraZeneca 40
Testing effectiveness (Phase 2)WithdrawnNCT03746249
What this trial is testing

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University
Testing effectiveness (Phase 2)Study completedNCT03322540
What this trial is testing

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Who this might be right for
Lung Cancer
Incyte Corporation 154
Testing effectiveness (Phase 2)Ended earlyNCT04521621
What this trial is testing

Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 76
Testing effectiveness (Phase 2)Study completedNCT03776136
What this trial is testing

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Who this might be right for
Advanced Melanoma
Merck Sharp & Dohme LLC 103
Large-scale testing (Phase 3)Study completedNCT03829332
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 623
Large-scale testing (Phase 3)Looking for participantsNCT05239741
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 100
Large-scale testing (Phase 3)Study completedNCT03358472
What this trial is testing

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Who this might be right for
Head and Neck Cancer
Incyte Corporation 89
Large-scale testing (Phase 3)Study completedNCT02220894
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 1,274
Large-scale testing (Phase 3)Study completedNCT04882241
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Merck Sharp & Dohme LLC 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Large-scale testing (Phase 3)Study completedNCT04199104
What this trial is testing

Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 511
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation